Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Day One Biopharmaceuticals (DAWN) Non Operating Income (2022 - 2025)

Day One Biopharmaceuticals (DAWN) has disclosed Non Operating Income for 4 consecutive years, with $18.5 million as the latest value for Q4 2025.

  • On a quarterly basis, Non Operating Income rose 46220.0% to $18.5 million in Q4 2025 year-over-year; TTM through Dec 2025 was $18.5 million, a 230.56% increase, with the full-year FY2025 number at $18.5 million, up 1416.19% from a year prior.
  • Non Operating Income was $18.5 million for Q4 2025 at Day One Biopharmaceuticals, up from -$9.8 million in the prior quarter.
  • In the past five years, Non Operating Income ranged from a high of $18.5 million in Q4 2025 to a low of -$9.8 million in Q3 2025.
  • A 4-year average of $3.1 million and a median of $40000.0 in 2024 define the central range for Non Operating Income.
  • Peak YoY movement for Non Operating Income: soared 108975.0% in 2024, then tumbled 918.63% in 2025.
  • Day One Biopharmaceuticals' Non Operating Income stood at $4.7 million in 2022, then soared by 263.75% to $17.2 million in 2023, then plummeted by 99.77% to $40000.0 in 2024, then skyrocketed by 46220.0% to $18.5 million in 2025.
  • Per Business Quant, the three most recent readings for DAWN's Non Operating Income are $18.5 million (Q4 2025), -$9.8 million (Q3 2025), and $4.7 million (Q2 2025).